Collaborations and partnerships are an essential part of our business strategy and we are open to discussing partnering opportunities either relating to our proprietary programs in clinical development or our Spiegelmer* technology. We are actively collaborating with international pharmaceutical leaders, academic investigators worldwide and other research organizations to advance TME Pharma's portfolio.
At TME Pharma we believe in the value of collaboration. We are seeking partners who share our vision to create impactful therapies and bring our innovative technology to market. For more information on partnering or collaborating with TME Pharma please contact Business Development team at
The list below contains some of scientific advisors and collaborators established by TME Pharma.
|
more TME Pharma collaborates with Prof. Dr. Michael Hölzel, Director at the Institute for Experimental Oncology at University Hospital Bonn (UKB), Germany, on the ongoing GLORIA study. His research is driven by exploration of the complexity and dynamics of cellular and non-cellular interactions within the tumor microenvironment. He has long-standing research expertise in the field of tumor biology and functional genomics with a particular focus on neural crest derived tumors. Prof. Hölzel leads a research project to characterize the NOX-A12-mediated modulation of tumor microenvironment in glioblastoma patients by multiparameter immunofluorescence microscopy. Prof. Hölzel works in collaboration with Prof. Dr. Frank A. Giordano, Professor and Chair of the Department of Radiation Oncology at the University Medical Center Mannheim, Germany, and the lead investigator of the GLORIA trial. Dr. Giordano is an expert in precision radiation therapy and intraoperative irradiation of malignant tumors, and has received international recognition for his brain tumor research, including an award from the American Society of Radiation Oncology (ASTRO) and an honorary membership of the Spanish Society of Radiation Oncology (SEOR).
|
more TME Pharma collaborates with the U.S. National Cancer Institute (NCI), of the National Institutes of Health (NIH), to further explore the effects of TME Pharma’s lead compounds, the CXCL12 inhibitor NOX-A12 and the CCL2 inhibitor NOX-E36, individually and combined, on brain tumors. The research program is led by Mark R. Gilbert, M.D., Chief of the Neuro-Oncology Branch at the National Cancer Institute’s Center for Cancer Research (NCI/CCR), part of the NIH. The NCI will conduct preclinical testing in different combinations with immunomodulatory treatments, including immune checkpoint inhibitors. The various combinations will be tested in an array of experiments in three murine brain cancer models, with extensive and detailed characterization of the tumor microenvironment.
|
|
more TME Pharma and Merck & Co., Inc./MSD announced their second clinical collaboration on July 21, 2021 in the upcoming Phase 2 clinical trial to evaluate safety and efficacy of TME Pharma's anti-CXCL12 agent, NOX-A12, in combination with MSD’s anti-PD-1, Keytruda® (pembrolizumab) and two different chemotherapy regimens as second-line therapy in patients with microsatellite stable pancreatic cancer.
Metastatic solid tumors that do not respond to checkpoint inhibitors: The clinical trial and thus the collaboration were completed in H1 2021.
|
more TME Pharma collaborated with Prof. Dr. Dirk Jäger, and Dr. Niels Halama at the National Center for Tumor Diseases in Heidelberg, Germany, one of the leading centers for cancer research and treatment, to conduct their completed clinical trial in metastatic colorectal and pancreatic cancer.
|
